These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 10974184)

  • 41. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization.
    Lincoff AM
    Am J Cardiol; 1998 Oct; 82(8B):36P-42P. PubMed ID: 9809890
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question?
    Young JJ; Kereiakes DJ
    J Invasive Cardiol; 2002 Jul; 14(7):404-10. PubMed ID: 12082194
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism.
    Gowda RM; Khan IA; Vasavada BC; Sacchi TJ
    Am J Ther; 2004; 11(4):302-7. PubMed ID: 15266223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Westerhout CM; Boersma E
    Expert Opin Drug Saf; 2003 Jan; 2(1):49-58. PubMed ID: 12904124
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab.
    Kondo K; Umemura K
    Clin Pharmacokinet; 2002; 41(3):187-95. PubMed ID: 11929319
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current issues with glycoprotein IIb-IIIa antagonists.
    Schneider DJ
    Curr Drug Targets; 2011 Nov; 12(12):1813-20. PubMed ID: 21718238
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T; McGavin JK; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
    Tcheng JE
    Am J Cardiol; 1999 May; 83(9A):7E-11E. PubMed ID: 10357575
    [No Abstract]   [Full Text] [Related]  

  • 50. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
    Giordano A; Musumeci G; D'Angelillo A; Rossini R; Zoccai GB; Messina S; Coscioni E; Romano S; Romano MF
    Curr Drug Metab; 2016; 17(2):194-203. PubMed ID: 26652157
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
    N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bleeding complications of platelet glycoprotein IIb/IIIa inhibitor abciximab (ReoPro ).
    Trivedi SM; Shani J; Hollander G
    J Invasive Cardiol; 2002 Jul; 14(7):423-5. PubMed ID: 12082199
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.
    Brown DL; Fann CS; Chang CJ
    Am J Cardiol; 2001 Mar; 87(5):537-41. PubMed ID: 11230835
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    EPISTENT Investigators
    Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel: a meta-analysis of randomized trials.
    Pannu R; Andraws R
    Crit Pathw Cardiol; 2008 Mar; 7(1):5-10. PubMed ID: 18458661
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
    Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
    Leclerc JR
    Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial).
    Singh HS; Dangas GD; Guagliumi G; Yu J; Witzenbichler B; Kornowski R; Grines C; Gersh B; Dudek D; Mehran R; Stone GW
    Am J Cardiol; 2012 Oct; 110(7):940-7. PubMed ID: 22748356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.